John J.P. Kastelein

QRx Pharma (United States) — United States

Medicine · Health Sciences

165h-index135.7kcitations1.1kworks9.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(752), Diabetes, Cardiovascular Risks, and Lipoproteins(355), Cancer, Lipids, and Metabolism(223), Lipid metabolism and disorders(158), Cholesterol and Lipid Metabolism(117)

Publications1.1k total

Cholesteryl Ester Transfer Protein Inhibition and High-Density Lipoprotein Particle Composition: Consequences for Atherogenesis and Neurodegeneration
2026Open Access
Abstract 4368890: Cholesteryl Ester Transfer Protein (CETP) Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY Phase 3 Clinical Trials
Circulation·2025· 1 cited
Abstract 4368587: Obicetrapib in combination with ezetimibe on top of atorvastatin regresses atherosclerotic plaque lesions in APOE*3-Leiden.CETP mice
Circulation·2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
The Journal of Prevention of Alzheimer s Disease·2025· 4 citedOpen Access
IMPACT OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, OBICETRAPIB, ON LIPOPROTEIN(A) LEVELS: POOLED DATA FROM PHASE 3 CLINICAL TRIALS
American Journal of Preventive Cardiology·2025Open Access
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients
Journal of the American College of Cardiology·2025· 21 citedOpen Access
SAFETY AND EFFICACY OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION: FROM GENETICS TO OUTCOME TRIALS
American Journal of Preventive Cardiology·2025Open Access
EFFECT OF OBICETRAPIB ON NEW ONSET DIABETES IN PATIENTS WITH ELEVATED LDL-C RECEIVING MAXIMALLY TOLERATED STATIN THERAPY: POOLED ANALYSES OF THE BROADWAY AND BROOKLYN TRIALS
American Journal of Preventive Cardiology·2025Open Access
SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS AT HIGH CARDIOVASCULAR RISK
American Journal of Preventive Cardiology·2025Open Access
SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
American Journal of Preventive Cardiology·2025· 1 citedOpen Access
Obicetrapib alone and in combination with ezetimibe increases reverse cholesterol transport and does not affect VLDL production
Atherosclerosis·2025Open Access
Safety and efficacy of obicetrapib in patients at high cardiovascular risk
Atherosclerosis·2025Open Access
Low-dose obicetrapib significantly increases concentrations of lipophilic antioxidants, APOE, and S1P in HDL subfractions
Atherosclerosis·2025· 2 citedOpen Access
Safety and efficacy of cholesteryl ester transfer protein inhibition: From genetics to outcome trials
Atherosclerosis·2025Open Access
Efficacy and safety of combination obicetrapib with moderate-dose statins
Atherosclerosis·2025Open Access
Obicetrapib significantly increases plasma and high-density lipoprotein (HDL) levels of lipophilic antioxidants
Atherosclerosis·2025· 2 citedOpen Access
Obicetrapib reduces atherosclerosis and vascular inflammation, mainly by reducing non-HDL cholesterol, improves lesion stability and adds to the beneficial effects of ezetimibe
Atherosclerosis·2025Open Access
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics
American Heart Journal·2025· 5 citedOpen Access
A Drug–Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers
American Journal of Cardiovascular Drugs·2025· 2 citedOpen Access
RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study
Cardiovascular Research·2025· 3 citedOpen Access
page 1 of 57Next →

Frequent Co-authors

Paul M. Ridker(15), Wolfgang Köenig(14), Antonio M. Gotto(9), Jean MacFadyen(8), Jacques Genest(8), Alberto Lorenzatti(8), Francisco Antônio Helfenstein Fonseca(7), Robert J. Glynn(7), Tom Thurén(6), John C. LaRosa(6), Charles L. Shear(6), Philip J. Barter(6), Erik S.G. Stroes(6), S. Matthijs Boekholdt(6), Kausik K. Ray(6), Giulia Renda(5), Christie M. Ballantyne(5), Marcus Flather(5), Peter Libby(5), Peter Libby(5)